Effect of Semaglutide on the Psoriatic Lesions in Patients With Type 2 Diabetes Mellitus

Sponsor
University of Banja Luka
Study ID
NCT06475586
Phase
PHASE4
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 70 Years
Healthy Volunteers
Not accepted

Interventions

  • Semaglutide — DRUG
    0.25mg 4 weeks, 0.5mg per 4 weeks and 1.0mg per 4 weeks, totally 12 weeks

Study Details

The use of semaglutide in patients with DMT2 and psoriasis contributes to improving the clinical picture of psoriasis and reducing the inflammatory response

Key Dates

Start date
May 3, 2023
Status verified
Jun 2024
Primary completion
Mar 1, 2024
Completion
Jun 10, 2024

Study Design

Enrollment
30 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: semaglutide
    The initial dose of the medicine is 0.25 mg once a week, for the duration of 4 weeks. Then the dose is increased to 0.5 mg per week, for the duration of 4 weeks. After at least 4 weeks, the dose can be increased from 0.5 mg to 1 mg per 4 week. Totally 12 weeks
  • No Intervention: controled group
    Patients with DMT2 and psoriasis, who are already on metformin therapy in the maximally tolerated dose and other oral antidiabetics, except on therapy with GLP-1 RA and SGLT-2 inhibitors.

Primary Outcome Measure

clinical characteristics of patients with psoriasis [ Time Frame: up to 12 weeks ]

Related Studies